Weight loss jabs long term effects
- User
Weight loss jabs long term effects
Assistant
Weight loss injections, often referred to as "jabs," typically include medications like semaglutide (brand names: Wegovy, Ozempic) and tirzepatide (brand name: Mounjaro). These medications are increasingly being used for chronic weight management in individuals with obesity or overweight conditions and comorbid diseases. While they have shown promising short-term results, it's essential to consider their long-term effects. Here’s a detailed overview:
Semaglutide (Wegovy, Ozempic)
Short-Term Effects:
- Weight Loss: Clinical trials, such as the STEP program for semaglutide, have shown significant weight loss, with participants losing 10-15% of their body weight over 68 weeks.
- Improved Metabolic Parameters: Reductions in HbA1c, blood pressure, and improvements in lipid profiles.
- Appetite Suppression: Works by mimicking the GLP-1 hormone, which reduces appetite and slows gastric emptying.
Long-Term Effects:
-
Sustained Weight Loss:
- Evidence: The STEP 5 trial showed that participants who continued semaglutide for an additional year maintained their weight loss.
- Concerns: There is limited data beyond two years. It is unclear if the weight loss can be sustained indefinitely without continued use.
-
Cardiovascular Benefits:
- Evidence: The SUSTAIN and SELECT trials indicated reduced cardiovascular events in patients with type 2 diabetes.
- Long-Term: Potential for reduced cardiovascular morbidity and mortality, but more extended studies are needed.
-
Gastrointestinal Issues:
- Short-Term: Common side effects include nausea, vomiting, diarrhoea, and constipation.
- Long-Term: These side effects often diminish over time, but chronic gastrointestinal issues could persist in some individuals
-
Pancreatitis and Thyroid C-cell Tumours:
- Evidence: Animal studies have shown an increased risk of thyroid C-cell tumours. However, this has not been conclusively demonstrated in humans.
- Monitoring: Long-term users should be monitored for symptoms of pancreatitis and thyroid issues. Semaglutide carries a black box warning for the risk of thyroid C-cell tumours based on animal studies.
-
Gallbladder Disease:
- Rapid weight loss, a common effect of these medications, is a known risk factor for gallstone formation. Long-term users should be monitored for symptoms of gall bladder disease.
-
Mental Health:
- Evidence: Some GLP-1 agonists have been associated with improved mood and reduced symptoms of depression, likely due to weight loss and improved metabolic health.
- Concerns: There have been rare reports of suicidal ideation. The FDA is currently investigating a potential link between GLP-1 agonists and suicidal thoughts.
-
Dependency and Withdrawal:
- There is a concern that patients may become dependent on the medication to maintain weight loss. If the medication is discontinued, weight regain is common. This “yo-yo” dieting can have detrimental metabolic and psychological effects
Tirzepatide (Mounjaro)
Tirzepatide is a dual GIP and GLP-1 receptor agonist, which means it activates two hormones that help regulate blood sugar and appetite.
Short-Term Effects:
- Weight Loss: In the SURMOUNT-1 trial, participants lost up to 22.5% of their body weight over 72 weeks.
- Improved Metabolic Parameters: Significant improvements in HbA1c, blood pressure, and lipid profiles.
Long-Term Effects:
-
Sustained Weight Loss:
- Evidence: The SURMOUNT-2 trial is ongoing to assess the long-term efficacy and safety but results are not yet available
- Concerns: Like semaglutide, it is unclear if weight loss can be maintained without continued use.
-
Gastrointestinal Issues
- Similar to semaglutide, with nausea and diarrhoea being the most common.
-
Pancreatitis and Thyroid C-cell Tumours:
- Evidence: As with other GLP-1 agonists, there is a theoretical risk based on animal studies, but no conclusive evidence in humans.
- Monitoring: Long-term users should be monitored for symptoms of pancreatitis and thyroid issues. Tirzepatide also carries a black box warning for the risk of thyroid C-cell tumours based on animal studies.
-
Gallbladder Disease:
- As with semaglutide, there is an increased risk of gallstone formation due to rapid weight loss.
-
Cardiovascular Benefits:
- Evidence: Early data suggests potential cardiovascular benefits, but long-term studies are needed.
-
Mental Health
- As with semaglutide, the FDA is investigating a potential link between GLP-1 agonists and suicidal thoughts.
-
Dependency and Withdrawal
- As with semaglutide, there is a risk of weight regain if the medication is discontinued.
General Considerations
-
Lifestyle Changes:
- Medications should be used in conjunction with lifestyle changes, including diet and exercise. Relying solely on injections without addressing underlying behavioural factors may lead to weight regain once the medication is stopped.
-
Regular Monitoring:
- Long-term users should undergo regular medical check-ups to monitor for potential side effects, including metabolic parameters, thyroid function, and gastrointestinal health.
-
Individual Variability:
- Responses to these medications can vary widely. Some individuals may experience significant benefits with few side effects, while others may struggle with adverse reactions or limited efficacy.
Conclusion
Weight loss injections like semaglutide and tirzepatide offer promising results for long-term weight management, but their long-term effects are still not fully understood. While they have demonstrated benefits in terms of weight loss and metabolic health, potential risks, including gastrointestinal issues, pancreatitis, and thyroid concerns, need to be monitored. Patients considering these medications should do so under the guidance of a healthcare provider, with a comprehensive plan that includes lifestyle modifications and regular medical supervision.
Other models, same or similar prompt
Responses were produced in different, uncontrolled contexts (system prompts, settings, prior turns). This is not a benchmark.